GSK2141795

 

Topic mentions per year

Topic mentions per year

2010-2017
01220102017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Aberrant MAPK and PI3K pathway signaling may drive the malignant phenotype in NRAS-mutant and BRAFWT NRASWT metastatic melanoma… (More)
  • table 2
Is this relevant?
2017
2017
s in National Meetings: 1) Panagiotis A. Konstantinopoulos, Vicky Makker, William T. Barry, Joyce F. Liu, Neil S. Horowitz… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2015
2015
UNLABELLED AKT (a serine/threonine-specific protein kinase) regulates many cellular processes contributing to cytotoxic drug… (More)
  • table 1
  • table 2
  • figure 1
  • figure 1
  • figure 1
Is this relevant?
2015
2015
Our identification of dysregulation of the AKT pathway in ovarian cancer as a platinum resistance specific event led to a… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2014
2014
Tumor cells upregulate many cell signaling pathways, with AKT being one of the key kinases to be activated in a variety of… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Protein kinases are key regulators of cellular processes, and aberrant function is often associated with human disease… (More)
Is this relevant?
2011
2011
3003 Background: GSK795 is a potent pan-isoform inhibitor of AKT. The objectives were to define the maximum tolerated dose (MTD… (More)
Is this relevant?
2011
2011
3085 Background: The RAS/RAF/MEK and PI3K/AKT pathways are activated in many human cancers. GSK212 is a potent and selective… (More)
Is this relevant?
2011
2011
5064 Background: GSK795 is a potent, ATP-competitive, pan AKT inhibitor. The purpose of this study was to characterize the… (More)
Is this relevant?
Review
2010
Review
2010
IMPORTANCE OF THE FIELD The evolution of targeted therapies is dependent upon identification of cellular moieties that can be… (More)
Is this relevant?